A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
THB335-201 is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adults with CSU who remain symptomatic despite standard-of-care treatment. The study includes a Screening Period of up to 4 weeks, a 12-week Treatment Period, and a 4-week Follow-Up Period, for a total participant duration of approximately 20 weeks.
Epistemonikos ID: c9b3efaf52af11f36d716e6bd800e2adc72f0e4a
First added on: Aug 14, 2026